Rm. Lidon et al., A PILOT, EARLY ANGIOGRAPHIC PATENCY STUDY USING A DIRECT THROMBIN INHIBITOR AS ADJUNCTIVE THERAPY TO STREPTOKINASE IN ACUTE MYOCARDIAL-INFARCTION, Circulation, 89(4), 1994, pp. 1567-1572
Background The success of streptokinase in acute myocardial infarction
is hampered by the high failure rate to achieve early reperfusion. Th
is study evaluates the possible benefit of Hirulog (Biogen, Cambridge,
Mass), a direct thrombin inhibitor, as adjunct therapy to streptokina
se to enhance early patency and prevent rethrombosis. Heparin has been
shown to be of very limited benefits in this setting. Methods and Res
ults Forty-five patients were randomized to Hirulog or heparin (2:1 ra
tio). Coronary angiography documented a TIMI2 or 3 flow after 90 minut
es in 77% of the patients treated with Hirulog and streptokinase and i
n 47% of patients treated with heparin and streptokinase (P<.05) and a
fter 120 minutes in 87% and 47% of patients, respectively (P<.01). TIM
I 3 flow was established in 77% of patients with Hirulog compared with
40% with heparin (P<.02). The clinical outcome and the bleeding rate
were also favorable to Hirulog; no reocclusion was observed at late an
giography performed 4.7 days later. Conclusions Hirulog in this pilot
study significantly improved the early patency rate of the infarct-rel
ated artery with a favorable clinical profile. This new direct thrombi
n inhibitor exhibits promise as adjunctive therapy to thrombolysis.